Intra Arterial Heparin Flushing Increases Cereberal Blood Flow in Chronic Ischemic Stroke Patients
Abstract
BACKGROUND: Recently, stroke therapy is focused on reperfusion therapies for restoring cerebral blood flow (CBF) and minimizing the undesired effects of neuron ischemia. However, the thrombolytic therapy to restore CBF was restricted with narrow time window. On other hands, not many patients can reach the treatment immediately after the onset of stroke. A wider time window therapy that might increase CBF would probably helpful. This study aims to investigate the CBF improvement after intra arterial heparin flushing (IAHF) therapy in chronic stroke patients.
METHODS: A clinical trial was conducted with time sampling. We collected chronic ischemic stroke subjects (with stroke onset ≥30 days) within periods February-September 2015. We investigated CBF before and after IAHF treatment in 75 chronic stroke patients. The difference before and after IAHF treatment in subgroup which is classified with infarct size and lesion area was tested. CBF was measured using MRI Quality Arterial Spin Labeling (qASL) with region of interest around infarct lesion.
RESULTS: We found a significant CBF improvement (p<0.001) around infarct area after IAHF treatment with average 10.39mL/100g/min raised. CBF improvement was found in lacunar infarct (p<0.001) and non lacunar (p<0.001), also in infarct in cortical (p<0.05), subcortical (p<0.001) and both area (p<0.05).
CONCLUSION: IAHF is associated with increased CBF around infarct area and IAHF probably offers some benefit for chronic stroke.
KEYWORDS: IAHF, CBF, chronic stroke, ischemic, lacunar, non lacunar, cortical lesion, subcortical lesion
Full Text:
PDFReferences
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. AHA Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015; 131: e29-322, PMID.
Hurtado O, Pradili JM, Alonso-Escolano D, Lorenzo P, Sobrino T, Castillo J, et al. Neurorepair versus neuroprotection. Stroke. 2006; 21: 54-63, CrossRef.
Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002; 33: 1934-42, CrossRef.
Surjawan S, As'ad S, Ranakusuma TAS, Wijaya A. C-reactive protein and matrix metalloproteinase-9 are associated with outcome of ischemic stroke. Indones Biomed J. 2012; 4: 157-63, CrossRef.
Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 2010; 17: 197-218, CrossRef.
Ramos-Cabrer P, Campos F, Sobrino T, Castillo J. Targeting the ischemic penumbra. Stroke. 2011; 42 (Suppl 1): S7-11, CrossRef.
Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991; 78: 3114-3124, PMID.
Gutiérrez LM, Díez Tejedor E, Alonso de Leciñana M, Fuentes B, Carceller F, Roda JM. Thrombolysis and neuroprotection in cerebral ischemia. Cerebrovasc Dis. 2006; 21: 118-26, CrossRef.
Schellinger PD, Fiebach BJ, Mohr A, Ringleb PA, Jansen O, Hacke W. Thrombolytic therapy for ischemic stroke. Crit Care Med. 2001; 29: 1812-8, CrossRef.
Stroke Update [Internet]. Consensus Statement 2008: Should the time window for intravenous thrombolysis be extended? 7th Karolinska Stroke Update meeting on November 18, 2008 [cited 2014 Sep 25]. Available from:
www.strokeupdate.org/Cons_thrombolysis_2008.aspx/">http://www.strokeupdate.org/.
Hauck EF, Apostel S, Hoffmann JF, Heimann A, Kempski O. Capillary flow and diameter changes during reperfusion after global cerebral ischemia studied by intravital video microscopy. J Cereb Blood Flow Metab. 2004; 24: 383-91, CrossRef.
Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA,Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010; 468: 232-43, CrossRef.
Durran AC, Watts C. Current trends in heparin use during arterial vascular interventional radiology. Cardiovasc Intervent Radiol. 2012; 35: 1308-14, CrossRef.
Liang JF, Li Y, Yang VC. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation. Thromb Res. 2000; 97: 349-58, CrossRef.
Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost. 2002; 88: 282-7, PMID.
Dvorak M, Vlasin M, Dvorakova M, Rauser P, Lexmauova L, Gregor Z, et al. Heparin and its derivatives in the treatment of arterial trombosis: a review. Vet Med. 2010; 55: 523-46, article.
Coutinho J, de Bruijn SFTM, deVeber G, Stam J. Anticoagulation for cerebral venous sinus trombosis. Cochrane DB Syst Rev. 2011; 8: 1-21, CrossRef.
Lewis JH, Kerber CW, Wilson JH. Effects of fibrinolytic agents and heparin on intravascular clot lysis. Am J Physiol. 1964; 207: 1044-8, PMID.
Nassiri AA, Hakemi MS, Soulati M, Marashian M, Rahbar K, Azizi F. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease. Iranian J Kidney Dis. 2009; 3: 162-7, PMID.
Perrey S. Promoting motor function by excercising the brain. Brain Sciences. 2013; 3: 101-22, CrossRef.
Font MA, Arboix A, Krupinski J. Angiogenesis, neurogenesis and neuroplasticity in ischemic stroke. Curr Cardiol Rev. 2010; 6: 238-44, CrossRef.
Slevin M, Kumar P, Gaffney J, Kumar J, Krupinski J. Can angiogenesis be exploited to improve stroke outcome? Mechanism and therapeutic potential. Clin Sci. 2006; 111: 171-83, CrossRef.
Dalkara T, Arsava EM. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis. J Cereb Blood Flow Metab. 2012; 32: 2031-99, CrossRef.
Sterr A, Basto Conforto A. Plasticity of adult sensorimotor system in severe brain infacts: challenges and opportunities. Neural Plast. 2012; 2012: 970136, CrossRef.
Albertini R, Rindi S, Passi A, Pallavicini G, De Luca G. Heparin protection against Fe2+- and Cu2+-mediatedoxidation of liposomes. FEBS Lett. 1996; 383: 155-8, CrossRef.
Grant D, Long WF, Mackintosh G, Williamson FB. Heparins as essential antioxidants. Agents Actions. 1994; 41: 214-5, CrossRef.
Nawashiro H, Wada K, Nakai K, Sato S. Focal increase in cerebral blood flow after treatment with near-infrared light to the forehead in a patient in a persistent vegetative state. Photomed Laser Surg. 2012; 30: 231-3, CrossRef.
Mchendry LC. Cerebral vasodilator therapy in stroke. Stroke. 1972; 3: 686-91, CrossRef.
Ko NU, Achrol AS, Chopra M, Saha M, Gupta D, Smith WS, et al. Cerebral blood flow changes after endovascular treatment of cerebrovascular stenosis. AJNR Am J Neuroradiol. 2005; 26: 538-42, PMID.
Schaechter JD. Motor rehabilitation and brain plasticity after hemiparetic stroke. Prog Neurobiol. 2004; 73: 61-72, CrossRef.
DOI: https://doi.org/10.18585/inabj.v8i2.204
Copyright (c) 2016 The Prodia Education and Research Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute